Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy

Clinical Immunology

Volumn 148, Issue 2, 2013, Pages 287-298

  Liang, Spencer C ^a,b   Moskalenko, Marina ^a,c   Van Roey, Melinda ^a,d   Jooss, Karin ^a,e  

^a CELL GENESYS INC   (United States)

^b Nodality Inc   (United States)

^c GENENTECH INC   (United States)

^d FIVE PRIME THERAPEUTICS INC   (United States)

^e PFIZER INC   (United States)

Author keywords

Cancer immunotherapy; Costimulation; T cells; Tregs

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FOLATE RECEPTOR; FOLATE RECEPTOR 4; FOLATE RECEPTOR 4 ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GRANZYME B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

CANCER IMMUNOTHERAPY; COSTIMULATION; T CELLS; TREGS;

ANIMALS; ANTIBODIES; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASMS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, REGULATORY;

EID: 84879713764     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.011     Document Type: Article

References (40)

1. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
2. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61:4766-4772.
3. Miller A.M., Lundberg K., Ozenci V., Banham A.H., Hellstrom M., Egevad L., et al. CD4+ CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 2006, 177:7398-7405.
4. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9:606-612.
5. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
6. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
7. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
8. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002, 3:135-142.
9. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
10. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 2000, 192:295-302.
11. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 2000, 192:303-310.
12. Yamaguchi T., Hirota K., Nagahama K., Ohkawa K., Takahashi T., Nomura T., et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007, 27:145-159.
13. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59:3128-3133.
14. Rech A.J., Mick R., Martin S., Recio A., Aqui N.A., Powell D.J., et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 2012, 4:162. (134ra).
15. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005, 201:1591-1602.
16. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115:3623-3633.
17. Sampson J.H., Schmittling R.J., Archer G.E., Congdon K.L., Nair S.K., Reap E.A., et al. A pilot study of IL-2R alpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012, 7:e31046.
18. Matsushita N., Pilon-Thomas S.A., Martin L.M., Riker A.I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 2008, 333:167-179.
19. Teng M.W., Swann J.B., von Scheidt B., Sharkey J., Zerafa N., McLaughlin N., et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res. 2010, 70:2665-2674.
20. Castro F.V., Al-Muftah M., Mulryan K., Jiang H.R., Drijfhout J.W., Ali S., et al. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunol. Immunother. 2012, 61:1005-1018.
21. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003, 22:3188-3192.
22. Hege K.M., Jooss K., Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. 2006, 25:321-352.
23. Simmons A.D., Li B., Gonzalez-Edick M., Lin C., Moskalenko M., Du T., et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol. Immunother. 2007, 56:1653-1665.
24. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001, 194:823-832.
25. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3539-3543.
26. Li B., VanRoey M., Triebel F., Jooss K. Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy. Clin. Cancer Res. 2008, 14:3545-3554.
27. Simmons A.D., Moskalenko M., Creson J., Fang J., Yi S., VanRoey M.J., et al. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol. Immunother. 2008, 57:1263-1270.
28. Li B., Simmons A., Du T., Lin C., Moskalenko M., Gonzalez-Edick M., et al. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin. Immunol. 2009, 133:184-197.
29. Powell D.J., Felipe-Silva A., Merino M.J., Ahmadzadeh M., Allen T., Levy C., et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 2007, 179:4919-4928.
30. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
31. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3005-3010.
32. Fu J., Xu D., Liu Z., Shi M., Zhao P., Fu B., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
33. Xu L., Xu W., Jiang Z., Zhang F., Chu Y., Xiong S. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol. Ther. 2009, 8:66-72.
34. Wu L., Yun Z., Tagawa T., Rey-McIntyre K., Anraku M., de Perrot M. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. J. Thorac. Oncol. 2011, 6:1578-1586.
35. Mahnke K., Schonfeld K., Fondel S., Ring S., Karakhanova S., Wiedemeyer K., et al. Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120:2723-2733.
36. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
37. Quezada S.A., Peggs K.S., Simpson T.R., Shen Y., Littman D.R., Allison J.P. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 2008, 205:2125-2138.
38. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
39. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13:509-517.
40. Santegoets S.J., Stam A.G., Lougheed S.M., Gall H., Scholten P.E., Reijm M., et al. T cell profiling reveals high CD4+ CTLA-4+ T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol. Immunother. 2013, 62:245-256.